芴甲基 N-(3-溴丙基)氨基甲酸酯 | 186663-83-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 芴
• 中文名称: 芴甲基 N-(3-溴丙基)氨基甲酸酯
• 中文别名: 硼沙标准缓冲液；3-(Fmoc-氨基)丙基溴；芴甲基N-(3-溴丙基)氨基甲酸酯；硼沙标准缓冲液(PH=9)
• 英文名称: 3-(9-fluorenylmethoxycarbonylamino)propyl bromide
• 英文别名: 3-(Fmoc-amino)propyl bromide；3-(Fmoc-amino)bromopropane；(9H-Fluoren-9-yl)methyl (3-bromopropyl)carbamate；9H-fluoren-9-ylmethyl N-(3-bromopropyl)carbamate
• CAS: 186663-83-2
• 化学式: C₁₈H₁₈BrNO₂
• 分子量: 360.25
• InChiKey: XWBHEIFHCNVXPS-UHFFFAOYSA-N

物化性质

• 熔点：
  99-105 °C
• 沸点：
  506.4±33.0 °C(Predicted)
• 密度：
  1.380±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  22
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.28
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2924299090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335,H413
• 储存条件：
  储存温度应控制在2-8°C，需保持干燥并密封。

反应信息

• 作为反应物：
  描述：

  硫代水杨酸 、 芴甲基 N-(3-溴丙基)氨基甲酸酯 、 盐酸 在 water ethanol 、 n-hexane diethyl 作用下， 以 乙醇 、 sodium hydroxide 、 水 为溶剂， 反应 2.0h， 以with n-hexane - diethyl and either (2:1, 15 ml) to give 2-[3-(9-fluorenylmethoxycarbonylamino)-propylthio]benzoic acid (1.07 g)的产率得到2-[3-(9-Fluorenylmethoxycarbonylamino)-propylthio]benzoic acid
  参考文献：
  名称：

  Benzamide derivatives and their use as vasopressin antagonists

  摘要：

  本发明涉及一种具有血管加压素拮抗活性的新苯甲酰胺衍生物，其通式表示为（I）： ##STR1## 其中R.sup.1是芳基，可选择性地用较低的烷氧基等取代，R.sup.2是较低的烷基等，R.sup.3是氢等，R.sup.4是较低的烷氧基等，R.sup.5是氢等，A是NH等，E是 ##STR2## 等，X是--CH.dbd.CH--，--CH.dbd.N--或S，Y是CH或N，以及其药学上可接受的盐，制备方法和包含其的制药组合物。

  公开号：

  US06054457A1
• 作为产物：
  描述：

  氯甲酸-9-芴基甲酯 、 3-溴丙胺氢溴酸盐 在 sodium carbonate 作用下， 以 1,4-二氧六环 、 水 为溶剂， 生成 芴甲基 N-(3-溴丙基)氨基甲酸酯
  参考文献：
  名称：

  Design, development and evaluation of novel dual PPARδ/PPARγ agonists

  摘要：

  Type 2 diabetes is at epidemic proportions and thus development of novel pharmaceutical therapies for improving insulin sensitivity has become of paramount importance. The objectives of the current study were to develop novel dual PPAR gamma/delta agonists without the deleterious side effects associated with full PPAR gamma agonists. Docking simulations of 23 novel compounds within the ligand binding domain of PPAR gamma/delta were performed using AutoDock Vina which consistently reproduced experimental binding poses from known PPAR agonists. Comparisons were made and described with other docking programs AutoDock and Surflex-Dock (from SYBYL-X). Biological evaluation of compounds was accomplished by transcriptional promoter activity assays, quantitative PCR gene analysis for known PPAR gamma/delta targets as well as in vitro assays for lipid accumulation and mitochondrial biogenesis verses known PPAR agonists. We found one (compound 9) out of the 23 compounds evaluated, to be the most potent and selective dual PPAR gamma/delta agonist which did not display the deleterious side effects associated with full PPAR gamma agonists. (c) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.11.060

文献信息

• [EN] NOVEL RADIOLABELLED CXCR4-TARGETING COMPOUNDS FOR DIAGNOSIS AND THERAPY<br/>[FR] NOUVEAUX COMPOSÉS RADIOMARQUÉS DIAGNOSTIQUES ET THÉRAPEUTIQUES CIBLANT CXCR4
  申请人：PROVINCIAL HEALTH SERVICES AUTHORITY

  公开号：WO2020210919A1

  公开（公告）日：2020-10-22

  This application relates to compounds of Formula (I): [targeting peptide]-N(R1)-X1(R2)L1-[linker]-RX n1 (I). The targeting peptide is cyclo[L-Phe-L-Tyr-L-Lys(iPr)-D-Arg-L-2-Nal-Gly-D-Glu]-L-Lys(iPr). R1 is H or methyl. X1 is an optionally substituted C1-C15 hydrocarbon optionally comprising heteroatoms. R2 is C(O)OH or C(O)NH2. L1 is a linkage (thiolether, amide, maleimide-thiol, triazole). The linker has a net negative charge at physiological pH and is a linear or branched chain of 1-10 units of X2L2 and/or X2(L2)2, wherein: each X2 is, independently, an optionally substituted C1-C15 hydrocarbon optionally comprising heteroatoms; and each L2 is a linkage. The linker optionally further comprises an albumin binder bonded to an L2. Each RX is a radiolabelling group linked through a separate L2, selected from: a metal chelator; a prosthetic group containing trifluoroborate (BF3); or a prosthetic group containing a silicon-fluorine-acceptor moiety. The compounds may be useful for imaging CXCR4-expressing tissues or for treating CXCR4-associated diseases or conditions (e.g. cancer).

  这个应用涉及到Formula (I)的化合物：[靶向肽]-N(R1)-X1(R2)L1-[连接物]-RX n1 (I)。靶向肽是cyclo[L-Phe-L-Tyr-L-Lys(iPr)-D-Arg-L-2-Nal-Gly-D-Glu]-L-Lys(iPr)。R1是H或甲基。X1是一个可选择地取代的含有杂原子的C1-C15烃。R2是C(O)OH或C(O)NH2。L1是一个连接物（硫醚、酰胺、马来酰亚胺-硫醇、三唑）。连接物在生理pH下具有净负电荷，是由1-10个X2L2和/或X2(L2)2的线性或支链构成，其中：每个X2独立地是一个可选择地取代的含有杂原子的C1-C15烃；每个L2是一个连接物。连接物可选择地进一步包括与L2结合的白蛋白结合剂。每个RX是通过单独的L2连接的放射标记基团，选自：金属螯合剂；含三氟硼酸盐（BF3）的假体基团；或含硅-氟受体基团的假体基团。这些化合物可能对于成像CXCR4表达组织或治疗与CXCR4相关的疾病或症状（如癌症）有用。
• HEPARAN SULFATE/HEPARIN MIMETICS WITH ANTI-CHEMOKINE AND ANTI-INFLAMMATORY ACTIVITY
  申请人：California Institute of Technology

  公开号：US20150038455A1

  公开（公告）日：2015-02-05

  The present disclosure provides for methods and compositions comprising a series of synthetic glycopolymers. The disclosure also relates to a kit which is suitable for carrying out the inventive methods.

  本公开提供了一系列合成糖聚合物的方法和组合物。该公开还涉及一种适用于执行创新方法的试剂盒。
• TAILORED GLYCOPOLYMERS AS ANTICOAGULANT HEPARIN MIMETICS
  申请人：California Institute of Technology

  公开号：US20150038436A1

  公开（公告）日：2015-02-05

  The present disclosure provides for methods and compositions comprising a series of synthetic glycopolymers. The disclosure also relates to a kit which is suitable for carrying out the inventive methods.

  本公开提供了一系列合成糖聚合物的方法和组合物。该公开还涉及一种适用于实施创新方法的试剂盒。
• [EN] RADIOLABELED COMPOUNDS TARGETING THE PROSTATE-SPECIFIC MEMBRANE ANTIGEN<br/>[FR] COMPOSÉS RADIOMARQUÉS CIBLANT L'ANTIGÈNE MEMBRANAIRE SPÉCIFIQUE DE LA PROSTATE
  申请人：PROVINCIAL HEALTH SERVICES AUTHORITY

  公开号：WO2020252598A1

  公开（公告）日：2020-12-24

  A compound comprising a prostate specific membrane antigen (PSMA)-targeting moiety of the following formula or of a salt or a solvate thereof. R0 is O or S. Each of R1a, R1b and R1c may be –CO2H, –SO2H, –SO3H, –PO2H, or –PO3H2, for example. R2 may be methylene or a derivative thereof, propylene or a derivative thereof, or a derivative of ethylene, optionally substituted. R3 is a linker. When the PSMA-targeting moiety is linked to a radiolabeling group, the compound may be used as an imaging agent or therapeutic agent for PSMA-expressing diseases/conditions.

  一种化合物，包括以下结构式或其盐或溶剂化合物的前列腺特异性膜抗原（PSMA）靶向基团。R0为O或S。R1a、R1b和R1c中的每一个可以是-CO2H、-SO2H、-SO3H、-PO2H或-PO3H2，例如。R2可以是亚甲基或其衍生物、丙烯基或其衍生物，或乙烯的衍生物，可选择性地取代。R3是一个连接基。当PSMA靶向基团与放射标记基团连接时，该化合物可用作PSMA表达疾病/病况的成像剂或治疗剂。
• [EN] AN OSTEOADSORPTIVE FLUOROGENIC SUBSTRATE OF CATHEPSIN K FOR IMAGING OSTEOCLAST ACTIVITY AND MIGRATION<br/>[FR] SUBSTRAT FLUOROGÈNE OSTÉOADSORBANT DE CATHEPSINE K POUR L'IMAGERIE DE L'ACTIVITÉ ET DE LA MIGRATION DES OSTÉOCLASTES
  申请人：UNIV CALIFORNIA

  公开号：WO2019018238A1

  公开（公告）日：2019-01-24

  In certain embodiments osteoadsorptive fluorogenic substrates of cathepsin K (or other proteases) are provided. Utilizing a bisphosphonate targeting moiety, the fluorogenic substrates provide effective bone-targeted protease sensor(s). In certain embodiments the "probes" comprise cleavable fluorophore-quencher pair linked by a cathepsin K (or other protease) peptide substrate and tethered to a bisphosphonate. Unlike existing probes that are cleared within a few days in vivo, the probes described herein (e.g., OFS-1) allow for monitoring resorption over the course of longer time periods with a single dose.

  在某些实施例中，提供了钙蛋白酶K（或其他蛋白酶）的骨吸收荧光底物。利用双磷酸盐靶向基团，荧光底物提供有效的靶向骨蛋白酶传感器。在某些实施例中，“探针”包括可切割的荧光团-猝灭剂对，由钙蛋白酶K（或其他蛋白酶）肽底物连接，并与双磷酸盐相连。与现有的在体内几天内被清除的探针不同，本文所述的探针（例如OFS-1）允许在单剂量下监测骨吸收的长时间进程。